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between QALY scores and scores on instruments regularly used
in schizophrenia studies such as the PANSS or the CGI, in order
to see if it is possible to construct reliable ‘crosswalks’ between
such clinical measures and the QALY-generating scores.
RESULTS: The limited evidence in the ﬁeld suggests that the cal-
culation of QALYs to quantify the adverse effects of schizo-
phrenia is difﬁcult. Nevertheless, usefulness of such calculation
for a proper estimation of the true burden of schizophrenia
cannot be ignored. Data from a large observational study, fol-
lowing 600 people with schizophrenia over three years, are used
to analyse the correlation between utility-generating scores from
EQ-5D and schizophrenia speciﬁc measures of clinical circum-
stances such as the PANSS, the MADRS, the AIMS measure of
side effects, the Simpson-Angus measure of side effects and the
Barnes Akathisia Rating Scale to see how generic instruments
such as EQ-5D perform in evaluating different health states in
Schizophrenia. CONCLUSIONS: Although the EQ-5D index
does not capture the changes in quality of life associated with
symptoms changes, it may be reasonably valid for calculating
QALYs for patients with schizophrenia.
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OBJECTIVES: 1) To describe the long term evolution of HRQL
of outpatients with schizophrenia, and 2) to analyse its associa-
tion with antipsychotic use. METHODS: SOHO is an ongoing,
3-year, observational study of the treatment of schizophrenia in
ten European countries. The primary objective of SOHO is to
assess the costs and outcomes of treatment of schizophrenia
using antipsychotics. Together with clinical measures, the EQ-
5D (VAS score and tariffs) were administered at baseline, and 3,
6, 12, 18, and 24 months. The ‘panel analysis’ approach was
used, since the outcomes were measured for the distinct post
baseline epochs (0–6, 6–12, 12–18, and 18–24 months of treat-
ment). Multivariate modeling was performed for each epoch,
adjusting for baseline differences among patients. When using
the second and subsequent episodes of patient treatment the
baseline covariates were derived from the covariates collected
when the patient switched treatment. RESULTS: A total of 8109
patients were included in this analysis (44% women; mean age:
40); 24-month retention was 78.47%. Overall, the EQ-5D score
after each period of continuous treatment was: Baseline; mean
0.6 SD 0.32: (0–6 months): 0.76 SD 0.26; (6–12 months): 0.79
SD 0.24 (12–18 months): 0.81 SD 0.23; (18–24 months): 0.82
SD 0.23. Olanzapine-treated patients had statistically higher EQ-
5D utility improvements during the ﬁrst 6 months compared
with risperidone (difference in mean change: 0.041; 95% CI:
0.023–0.06)-, quetiapine (0.032; 0.006–0.059)-, oral (0.081;
0.057–0.105)- and depot typicals (0.077; 0.049–0.105)-treated
patients. No statistical separation was observed between olan-
zapine, clozapine and amilsupride groups. These differences
remain during the 24-month follow-up. CONCLUSIONS:
Antipsychotic treatment is associated with sustained improve-
ment in HRQL. The improvements in EQ-5D scores during the
ﬁrst 6 months for the Olanzapine group were signiﬁcantly higher
than the improvement for other antipsychotics and remaining
thereafter, with the exception of Amilsupride and Clozapine
where no signiﬁcant separation was found.
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OBJECTIVES: To deﬁne criteria for symptoms remission in
depression for reduced versions of the HDRS. METHODS: The
discriminative validity of the HDRS (HDRS-21 and 17 items)
and its shorter scales [Bech Melancholia Scale (BMS-6); Maier
& Philips Severity Scale (MPSS-6); Gibbons et al Depression
Scale (GDS-8); Evans et al Depression Scale (EDS-6)], was
assessed against the Clinical Global Impression of severity (CGI)
in a Spanish multicenter study. The study included 168 depres-
sive patients in ambulatory care. Of these, 118 patients were con-
sidered as clinically unstable (either because of presenting a
new/recurrent disease episode or because of needing an adjust-
ment/change of treatment). After six weeks, those patients were
reassessed by the HDRS and the CGI. The best cut-off points to
discriminate the criterion of clinical remission (CGI score = 1)
were found by using Receiver Operating Characteristic analyses
(ROC). The accuracy of the different versions was assessed by
analysing the area under the ROC curves (AUC). RESULTS: All
versions discriminated at baseline the severity of depression
according to the CGI criterion (all p-values < 0.005 by one-way
ANOVA corrected for multiple comparisons). Also, all versions
discriminated the severity of depression (remission versus no
remission) at six weeks of follow-up (all p-values < 0.0001 by t-
test analyses). The ROC analyses suggested the following cut-off
points to identify remission criteria in our sample (HDRS-21:
<=7; HDRS-17: <=7; BMS: <=2; MPSS: <=3; GDS: <=5; EDS:
<=4). The AUC showed similar accuracy for the HDRS-21,
HDRS-17 and the four shorter versions (AUC range from 0.89
to 0.95, chi2 (ﬁve df) = 8.72, p = 0.12). CONCLUSION: Com-
pared with the canonical versions of the HDRS (21 or 17 items),
shorter versions have showed similar accuracy to deﬁne remis-
sion of depressive symptoms.
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OBJECTIVES: To compare outcomes of patients receiving either
SSRI or SNRI antidepressants for Major Depression in primary-
care settings. METHODS: We analyzed data collected from 
an observational study in 47 primary care facilities in four 
Canadian provinces. Patients meeting DSM-IV-TR criteria for
major depression, >=18 years of age and scoring >=18 on the
HAMD-17 were assigned to groups assessed using HAMD-7 or
HAMD-17. All patients received SSRIs or SNRIs according to
their physician’s preference. Patient outcome was remission
(HAMD-17 <=, or HAMD-7 <=) after 8 treatment weeks.
RESULTS: Of the 337 patients, 159 (47.2%; 66.6% were
females) received SSRIs (citalopram-110, ﬂuoxetine-9, paroxe-
tine-37 and sertraline-3), and 178 (52.8%, 67.4% were females)
received SNRIs (venlafaxine-XR). Mean age was 42.0 ± 13.6 for
SSRIs and 43.7 ± 13.7 for SNRIs (P = 0.60). SSRI-treated
